The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-74
SponsorThe First Affiliated Hospital of Guangzhou Medical University

About this trial

AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in nodule detection and workflow optimization. However, their effectiveness in resource-limited community centers requires thorough evaluation.

This RCT compares AI-assisted versus manual CT interpretation across community health centers. Expert radiologists will establish reference standards, while an independent committee blindly evaluates cases from both groups. The study assesses diagnostic accuracy, operational efficiency, and cost-effectiveness, with blinded analysts resolving discrepancies through consensus to ensure reliable results.

Eligibility criteria

Qualifiers

Aged 45-74 years

Permanent resident of participating study communities

No prior history of lung cancer and no lung cancer screening within the past 3 months

Able to comprehend and voluntarily sign informed consent, with willingness to participate in long-term follow-up

Disqualifiers

Individuals with a confirmed diagnosis of lung cancer

Those with severe comorbidities contraindicating CT imaging

Inability to understand study protocols or provide informed consent due to cognitive impairment

Concurrent participation in other clinical trials that may interfere with study outcomes

Trial design

Treatments tested in this trial

  • AI

Treatment groups

7,294 Participants
are divided into 2 treatment groups